First licensed treatment for hidradenitis suppurativa

The licence for Humira (adalimumab) has been extended to include the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults who have had an inadequate response to conventional HS therapy

HS is a painful, chronic systemic inflammatory disorder, characterised by inflamed nodules, boils and abscesses located particularly around the groin and underarm.
‘The approval of Humira to treat moderate to severe HS is a major step forward in supporting patients with this distressing and life-changing condition,’ said Dr David Fitzgerald, consultant dermatologist at Salford Royal NHS Foundation Trust. ‘Patients with HS can experience immense pain and the condition often dramatically affects their psychological wellbeing and quality of life.’
The benefits and risks of long-term treatment should be regularly evaluated and if treatment is interrupted, Humira may be reintroduced at the maintenance dose of 40mg per week.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Flu antivirals approved for NHS prescribing as cases increase

Flu antivirals approved for NHS prescribing as cases increase

GPs can now prescribe antiviral medicines for flu prophylaxis...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

New e-cigarette alternative launched on prescription

New e-cigarette alternative launched on prescription

Voke, a new nicotine inhaler, is available to prescribe...

Smoking Cessation Treatment Options

Smoking Cessation Treatment Options

Types and suitabilities of smoking cessation treatments.